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Introduction
Nitric oxide is a key signalling molecule that is involved in
the regulation of a variety of biological and physiological
processes. Soluble Guanylate Cyclase (sGC) is considered
as the main receptor for this gaseous molecule, and catal-
yses the conversion of GTP to cyclic GMP. sGC is a het-
erodimer, consisting of an alpha1 or alpha2 subunit and
a beta1 subunit. This beta1 subunit contains an evolution-
ary conserved N-terminal heme-binding domain. A pros-
thetic ferrous heme group, which is crucial for the sensing
of NO, is positioned in this domain via its interaction
with the axial ligand histidine-105 and a number of
anchoring residues. Binding of NO to the Fe2+ ion of the
penta-coordinated histidyl-heme complex, eventually
leads to cleavage of the heme-histidine bond. This cleav-
age is the molecular switch that leads to a ~200-fold acti-
vation of sGC. Removal of this heme moiety as well as its
oxidation abolishes any NO-induced enzyme activation.
To differentiate between the sGC-dependent and sGC-
independent functions of NO, and to differentiate
between heme-dependent and heme-independent activi-
ties of sGC, we generated heme-deficient sGCbeta1
H105F knock in (KI) mice in which sGC retains its basal
activity, but can no longer be activated by NO. These mice
might furthermore form a model for sGC with a non-
functional heme group as in oxidative stress.
Materials and methods
Full sGCbeta1 H105F knock in mice were generated using
a classical approach by which the sGCbeta1 allele was
replaced by a mutated allele by means of homologous
recombination. As such, the codon for the histidine-105
residue of the sGCbeta1 subunit was replaced by a codon
for a fenylalanine. Initially, mice were phenotyped on a
mixed background of 129S6 × C57Bl/6J or 129S6 × CD1.
Non-invasive basal systolic blood pressure (SBP) and
heart rate (HR) measurements were performed in male
and female wild-type (WT) and sGC beta1 H105F knock
in mice with a tail-cuff pressure-recording device (Visitech
BP-2000).
Results
sGCbeta1 H105F knock in mice showed a reduced life
span, gastro-intestinal tract abnormalities, and growth
retardation. Basal SBP was higher in sGCbeta1 KI mice
than in WT mice (142 ± 15 vs. 113 ± 8 mmHg, P < 0.001),
while HR was lower in sGCbeta1 KI compared to their WT
littermates (513 ± 53 vs. 639 ± 62 bpm, P < 0.001). Relax-
ation of precontracted aortic rings was impaired.
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The NO-activated state of sGC is necessary for the normal
function of a number of important physiological proc-
esses in the body. It is important for the regulation of car-
diovascular homeostasis, such as the control of blood
pressure and heart rate. It is necessary for normal gastro-
intestinal tract function and development, and essential
for normal growth and viability.Page 2 of 2
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